JP2024526334A - 肥大型心筋症を治療するための方法 - Google Patents

肥大型心筋症を治療するための方法 Download PDF

Info

Publication number
JP2024526334A
JP2024526334A JP2024501787A JP2024501787A JP2024526334A JP 2024526334 A JP2024526334 A JP 2024526334A JP 2024501787 A JP2024501787 A JP 2024501787A JP 2024501787 A JP2024501787 A JP 2024501787A JP 2024526334 A JP2024526334 A JP 2024526334A
Authority
JP
Japan
Prior art keywords
lvot
compound
lvef
acceptable salt
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526334A5 (enExample
Inventor
ファディー マリク，
スチュアート カプファー，
スティーブン ビー． ハイトナー，
ローラ アン ロバートソン，
リーシン メン，
アナ アズムケイナ，
チー ウォルトマン，
Original Assignee
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82850823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2024526334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2024526334A publication Critical patent/JP2024526334A/ja
Publication of JP2024526334A5 publication Critical patent/JP2024526334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
JP2024501787A 2021-07-16 2022-07-15 肥大型心筋症を治療するための方法 Pending JP2024526334A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163203333P 2021-07-16 2021-07-16
US63/203,333 2021-07-16
US202263299753P 2022-01-14 2022-01-14
US63/299,753 2022-01-14
US202263305609P 2022-02-01 2022-02-01
US63/305,609 2022-02-01
US202263331197P 2022-04-14 2022-04-14
US63/331,197 2022-04-14
US202263343975P 2022-05-19 2022-05-19
US63/343,975 2022-05-19
PCT/US2022/073808 WO2023288324A1 (en) 2021-07-16 2022-07-15 Methods for treating hypertrophic cardiomyopathy

Publications (2)

Publication Number Publication Date
JP2024526334A true JP2024526334A (ja) 2024-07-17
JP2024526334A5 JP2024526334A5 (enExample) 2025-07-23

Family

ID=82850823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501787A Pending JP2024526334A (ja) 2021-07-16 2022-07-15 肥大型心筋症を治療するための方法

Country Status (22)

Country Link
US (4) US20230058927A1 (enExample)
EP (2) EP4370116B1 (enExample)
JP (1) JP2024526334A (enExample)
KR (1) KR20240047359A (enExample)
AU (1) AU2022312506A1 (enExample)
CA (1) CA3225787A1 (enExample)
CL (2) CL2024000090A1 (enExample)
DK (1) DK4370116T3 (enExample)
ES (1) ES3014965T3 (enExample)
FI (1) FI4370116T3 (enExample)
HR (1) HRP20250174T1 (enExample)
HU (1) HUE070699T2 (enExample)
IL (1) IL310140A (enExample)
LT (1) LT4370116T (enExample)
MX (1) MX2024000804A (enExample)
PL (1) PL4370116T3 (enExample)
PT (1) PT4370116T (enExample)
RS (1) RS66640B1 (enExample)
SI (1) SI4370116T1 (enExample)
SM (1) SMT202500098T1 (enExample)
TW (1) TW202320763A (enExample)
WO (1) WO2023288324A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
EP4370116B1 (en) * 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) * 2022-08-04 2025-08-07 サイトキネティックス， インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292695A1 (en) * 2005-06-22 2006-12-28 Roslin Institute Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells
IL322175A (en) * 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
WO2020257609A1 (en) 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4249474A4 (en) 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス， インコーポレイテッド アフィカムテンを調製するための工程
CN119789856A (zh) 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス， インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024050139A1 (en) 2022-09-02 2024-03-07 AnaBios Corporation Therapeutic uses of cardiac myosin inhibitors
EP4604841A1 (en) 2022-10-21 2025-08-27 Prolaio, Inc. System and method of treatment of hypertrophic cardiomyopathy
WO2024097284A1 (en) 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
EP4666076A1 (en) 2023-02-17 2025-12-24 Bristol-Myers Squibb Company Methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels
WO2024182469A1 (en) 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
CN122070481A (zh) 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
""2020 AHA/ACC Guideline for the Diagnosisand Treatment of Patients With Hypertrophic Cardiomyopathy", CIRCULATION, vol. Volume 142, Issue 25, JPN6026032372, 2020, pages 558 - 631, ISSN: 0005920270 *
""Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Ob", CIRCULATION: HEART FAILURE, vol. Volume 13, Issue 6, Article e006853, JPN6026032370, 2020, ISSN: 0005920268 *
"A MULTI-CENTER, RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SA, vol. Version 23, JPN6026032369, 7 May 2021 (2021-05-07), ISSN: 0005920267 *
"FORM 8-K, CURRENT REPORT", JPN6026032371, 7 October 2021 (2021-10-07), ISSN: 0005920269 *

Also Published As

Publication number Publication date
KR20240047359A (ko) 2024-04-12
RS66640B1 (sr) 2025-04-30
US12370179B1 (en) 2025-07-29
IL310140A (en) 2024-03-01
MX2024000804A (es) 2024-02-06
PL4370116T3 (pl) 2025-04-28
CA3225787A1 (en) 2023-01-19
US20260097021A1 (en) 2026-04-09
HRP20250174T1 (hr) 2025-04-11
CL2024000090A1 (es) 2024-08-16
CL2024001945A1 (es) 2024-12-06
EP4370116A1 (en) 2024-05-22
US20250177357A1 (en) 2025-06-05
PT4370116T (pt) 2025-03-14
EP4370116B1 (en) 2025-01-15
HUE070699T2 (hu) 2025-06-28
WO2023288324A1 (en) 2023-01-19
ES3014965T3 (en) 2025-04-28
DK4370116T3 (da) 2025-02-03
LT4370116T (lt) 2025-04-10
SI4370116T1 (sl) 2025-04-30
TW202320763A (zh) 2023-06-01
SMT202500098T1 (it) 2025-03-12
EP4548912A2 (en) 2025-05-07
AU2022312506A1 (en) 2024-02-01
FI4370116T3 (fi) 2025-03-04
US20230058927A1 (en) 2023-02-23
EP4548912A3 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
EP4370116B1 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2025523921A (ja) 非閉塞性肥大型心筋症を治療するための方法
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
JP2025525913A (ja) 閉塞性肥大型心筋症を治療するための方法
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
WO2024081611A1 (en) Methods for treating heart failure by administering cardiac sarcomere activators
WO2024097284A1 (en) Mavacamten and derivatives thereof for use in treating atrial dysfunction
HK40110429A (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
HK40110429B (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
HK40105016A (en) Methods for treating hypertrophic cardiomyopathy
CN117794535A (zh) 用于治疗肥厚型心肌病的方法
HK40122885A (en) Methods for treating obstructive hypertrophic cardiomyopathy
HK40122886A (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
US20250295639A1 (en) Methods for treating heart diseases
JP7439297B2 (ja) 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法
Kistler et al. Management of atrial fibrillation
EP4351566A1 (en) Safe administration of mmp-12 inhibitor
WO2008134602A1 (en) Levosimendan dosage regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260730